Agenus Inc., an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies, today announced the closing of its immuno-oncology (I-O) partners...
In 2018, the U.S. Food and Drug Administration (FDA) approved 59 novel drugs, meaning approved new molecular entities (NMEs). The figure for 2017 was 46 novel drugs. The FDA notes, “Each year, CDER a...
Gilead Sciences has signed a licensing and collaboration agreement, potentially worth $785m, with South Korea-based Yuhan to develop new therapeutic candidates for the treatment of advanced fibrosis d...
Gilead Sciences and Agenus announced the companies have entered into an immuno-oncology partnership focused on the development and commercialization of up to five novel immuno-oncology therapies.
Gilead Sciences and Tango Therapeutics, a company focused on the discovery and development of novel cancer therapies, announced a global strategic collaboration.
Gilead Sciences and Precision BioSciences announced that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV).
According to the agreement Pharmstandard production facilities will manufacture Sovaldi® for the treatment of chronic hepatitis C and Truvada® for the treatment of HIV.
Gilead Sciences announced that the European Commission has granted Marketing Authorization for Biktarvy®, a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection.
Hookipa Biotech AG, an Austrian clinical-stage biotech company, and Gilead Sciences, a research-based biopharmaceutical company, entered into a research collaboration and license agreement.
The new site in Hoofddorp will enable Kite to efficiently manufacture and deliver its cell therapies to people living with cancer in Europe and will provide more than 300 new jobs when fully operational in 2020.
Gilead Sciences and Verily Life Sciences announced a scientific collaboration using Verily’s platform to identify and better understand the immunological basis of three common and serious inflammatory diseases.
Kite, a Gilead Company, and Sangamo Therapeutics entered into a worldwide collaboration using Sangamo’s zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies in oncology.
ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline with Pfizer Inc. and Shionogi Ltd., announced that it has filed patent infringement litigation against Gilead Sciences
Kite, a Gilead Company, announced a clinical trial collaboration with Pfizer to evaluate the safety and efficacy of the investigational combination of Yescarta and Pfizer's utomilumab
Gilead Sciences and its subsidiary Kite announced that they have entered into a definitive agreement under which they have agreed to acquire Cell Design Labs
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OK